Significance of rs1271572 in the estrogen receptor beta gene promoter and its correlation with breast cancer in a southwestern Chinese population

Journal of Biomedical Science

Jun Jiang²  Xiangdong Luo¹  Xianchun Chen²  Lingling Zhang¹  Juhui Qiu¹  Yan Liang²  Li Chen² 

[1] Burn Research Institute, Southwest Hospital, Third Military Medical University, Chongqing, 400038, P. R. China;Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, P.R. China

关键词: Chinese;    Prognosis;    Estrogen receptor beta;    SNP;    Breast cancer;   

Others  :  823875
DOI  :  10.1186/1423-0127-20-32

 received in 2013-02-09, accepted in 2013-05-21,  发布年份 2013

【 摘 要 】

Background

To characterize single nucleotide polymorphisms (SNPs) within the promoter region of the estrogen receptor beta (ERβ) gene and to analyze the association of ERβ SNPs with susceptibility to breast cancer. Genotype frequencies of five SNPs (rs3020449, rs3020450, rs2987983, rs1271572 and rs1887994) in the promoter region of the ERβ gene in 873 women with breast cancer, 645 women with fibroadenoma and 700 healthy women were determined using an allele-specific tetra-primer polymerase chain reaction (PCR). Kaplan-Meier survival analysis was performed to evaluate the association of selected rs1271572 with prognosis in breast cancer. Electrophoretic mobility-shift assays were conducted to explore the binding of SNP rs1271572 containing probes to transcriptional factor Ying Yang 1 (YY1).

Results

Women with the homozygous TT genotype of rs1271572 had a significantly higher risk in developing breast cancer. Breast cancer patients with the TT genotype of rs1271572 had lower five-year survival rates than those with other genotypes and were more likely to suffer brain metastases. The rs1271572 G→T SNP abrogated YY1 binding and reduced the transcription activity of the promoter 0 N in the ERβ gene in vitro.

Conclusions

TT genotype of rs1271572 is associated with increased risk for breast cancer in Chinese women and is associated with unfavored prognosis in Chinese breast cancer patients. TT genotype of rs1271572 inhibited expression of ERβ gene by down regulating transcriptional activity of the promoter 0 N in the ERβ gene. Our data revealed that the TT genotype of rs1271572 resulted in loss of the YY1 binding site and reduced the transcription activity of the promoter 0 N in the ERβ gene.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [2]Chen XY, Kong ZL: Chinese Cancer Registry Annual Report 2009. In Book [Chinese Cancer Registry Annual Report 2009] Edited by Press Military Medical Science. 2010, 26-28.
• [3]Li GL, Chen WQ: Representativeness of population-based cancer registration in China–comparison of urban and rural areas. Asian Pac J Cancer Prev 2009, 10:559-564.
• [4]Yu KD, Rao NY, Chen AX: A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat 2011, 126:37-45.
• [5]Chen L, Qiu J, Yang C: Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Cancer Lett 2009, 278:210-219.
• [6]Fox EM, Davis RJ, Shupnik MA: ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids 2008, 73:1039-1051.
• [7]Roger P, Sahla ME, Mäkalä S: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-2541.
• [8]Treeck O, Elemenler E, Kriener C: Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 2009, 114:207-211.
• [9]Maguire P, Margolin S, Skoglund J: Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat 2005, 94:145-152.
• [10]Gold B, Kalush F, Bergeron J: Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 2004, 64:8891-8900.
• [11]Ichikawa S, Koller DL, Peacock M: Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women. J Clin Endocrinol Metab 2005, 90:5921-5927.
• [12]Nilsson M, Dahlman I, Jiao H: Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis — a cohort study. BMC Med Genet 2007, 8:73.
• [13]Harendza S, Lovett DH, Panzer U: Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003, 278:20490-20499.
• [14]Stevens A, Soden J, Brenchley PE: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003, 63:812-816.
• [15]Hirata S, Shoda T, Kato J: The multiple untranslated first exons system of the human estrogen receptor β (ER β) gene. J Steroid Biochem Mol Biol 2001, 78:33-40.
• [16]Zhao C, Lam EW, Sunters A: Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003, 22:7600-7606.
• [17]Kim BC, Kim WY, Park D: SNP@Promoter: a database of human SNPs (single nucleotide polymorphisms) within the putative promoter regions. BMC Bioinforma 2008, 1:S2. 9 Suppl
• [18]Abbas S, Beckmann L, MARIE-GENICA consortium on genetic susceptibility for menopausal hormone therapy related breast cancer risk: Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 2010, 126:2935-2946.
• [19]Cox DG, Bretsky P, Breast and Prostate Cancer Cohort Consortium: Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer 2008, 122:387-392.
• [20]Sun YH, Yang B, Wang XH: Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer. Zhonghua Wai Ke Za Zhi 2005, 43:948-951.
• [21]Qi J, Zhang J, Feng W: Promoting effect of IFN-gamma on the expression of LPS-induced IL-12 p40 and p35 mRNA in murine suppressor macrophages. Sci China C Life Sci 2000, 43:578-588.
• [22]Figtree GA, Noonan JE, Bhindi R, Collins P: Estrogen receptor polymorphisms: significance to human physiology, disease and therapy. Recent Pat DNA Gene Seq 2009, 3:164-171.
• [23]Herynk MH, Fuqua SA: Estrogen receptor mutations in human disease. Endocr Rev 2004, 25:869-898.
• [24]Fischer C, Juhasz-Boess I, Lattrich C: Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids. Gynecol Endocrinol 2010, 26:4-9.
• [25]Rexrode KM, Ridker PM, Hegener HH: Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Clin Chem 2007, 53:1749-1756.
• [26]Ye S, Dhillon S, Xiayi K, Collins AR, Day IN: An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001, 29:88-98.
• [27]Vinayagam R, Sibson DR, Holcombe C: Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer–a retrospective study. BMC Cancer 2007, 7:131. BioMed Central Full Text
• [28]Lindberg K, Ström A, Lock JG: Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 2010, 222:156-167.
• [29]Gruvberger-Saal SK, Bendahl PO, Saal LH: Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007, 13:1987-1994.
• [30]Rakha EA, Reis-Filho JS, Ellis IO: Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010, 120:293-308.
• [31]Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G: Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol 2012, 180:2120-2133.
• [32]Gordon S, Akopyan G, Garban H: Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006, 25:1125-1142.
• [33]Gordon S, Akopyan G, Garban H: YY1 is autoregulated through its own DNA-binding sites. BMC Mol Biol 2009, 10:85. BioMed Central Full Text
• [34]Lieberthal JG, Kaminsky M, Parkhurst CN: The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells. Breast Cancer Res 2009, 11:R42. BioMed Central Full Text
• [35]Thomassen M, Tan Q, Kruse TA: Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 2008, 8:394. BioMed Central Full Text